Universal Biosensors Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Universal Biosensors.

Wichtige Informationen

n/a

Wachstumsrate der Gewinne

n/a

EPS-Wachstumsrate

Medical Equipment Gewinnwachstum	16.0%
Wachstumsrate der Einnahmen	n/a
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	None
Zuletzt aktualisiert	n/a

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

We Think Universal Biosensors (ASX:UBI) Needs To Drive Business Growth Carefully

Nov 09

We're Keeping An Eye On Universal Biosensors' (ASX:UBI) Cash Burn Rate

May 03

We Think Universal Biosensors (ASX:UBI) Needs To Drive Business Growth Carefully

Jan 12

We're Keeping An Eye On Universal Biosensors' (ASX:UBI) Cash Burn Rate

Oct 10

Companies Like Universal Biosensors (ASX:UBI) Are In A Position To Invest In Growth

Apr 28

We Think Universal Biosensors (ASX:UBI) Can Afford To Drive Business Growth

May 13

Should You Take Comfort From Insider Transactions At Universal Biosensors, Inc. (ASX:UBI)?

Feb 24

We Think Universal Biosensors (ASX:UBI) Can Afford To Drive Business Growth

Jan 20

The Universal Biosensors (ASX:UBI) Share Price Has Gained 95% And Shareholders Are Hoping For More

Dec 15

In diesem Abschnitt stellen wir normalerweise Umsatz- und Gewinnwachstumsprognosen vor, die auf den Konsensschätzungen professioneller Analysten basieren, um den Anlegern zu helfen, die Fähigkeit des Unternehmens zur Gewinnerzielung zu verstehen. Da Universal Biosensors jedoch nicht genügend Daten aus der Vergangenheit zur Verfügung gestellt hat und keine Analystenprognose vorliegt, können die zukünftigen Erträge nicht zuverlässig durch Extrapolation von Vergangenheitsdaten oder anhand von Analystenprognosen berechnet werden.

Dies ist eine recht seltene Situation, da 97 % der von SimplyWall St erfassten Unternehmen über Finanzdaten aus der Vergangenheit verfügen.

Gewinn- und Umsatzwachstumsprognosen

ASX:UBI - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (AUD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
9/30/2024	7	-12	-15	-14	N/A
6/30/2024	7	-12	-11	-10	N/A
3/31/2024	7	-6	-16	-15	N/A
12/31/2023	7	-7	-16	-15	N/A
9/30/2023	5	-18	-11	-10	N/A
6/30/2023	4	-20	-17	-15	N/A
3/31/2023	4	-26	-17	-15	N/A
12/31/2022	5	-27	-16	-15	N/A
9/30/2022	5	-19	-16	-14	N/A
6/30/2022	5	-16	-15	-14	N/A
3/31/2022	6	-14	-13	-12	N/A
12/31/2021	6	-11	-11	-10	N/A
9/30/2021	6	-7	-10	-9	N/A
6/30/2021	6	-6	-9	-9	N/A
3/31/2021	4	-8	-9	-8	N/A
12/31/2020	3	-8	-9	-8	N/A
9/30/2020	3	-7	-16	-6	N/A
6/30/2020	4	-6	-20	-10	N/A
3/31/2020	6	-4	-20	-10	N/A
12/31/2019	7	-5	23	33	N/A
9/30/2019	14	-8	31	31	N/A
6/30/2019	60	35	39	39	N/A
3/31/2019	64	35	42	42	N/A
12/31/2018	69	38	1	2	N/A
9/30/2018	65	39	7	7	N/A
6/30/2018	24	-4	N/A	8	N/A
3/31/2018	25	-3	N/A	9	N/A
12/31/2017	25	-1	N/A	9	N/A
9/30/2017	26	6	N/A	1	N/A
6/30/2017	23	5	N/A	9	N/A
3/31/2017	22	5	N/A	8	N/A
12/31/2016	19	1	N/A	7	N/A
9/30/2016	17	-6	N/A	6	N/A
6/30/2016	20	-4	N/A	3	N/A
3/31/2016	19	-5	N/A	-2	N/A
12/31/2015	17	-7	N/A	-1	N/A
9/30/2015	18	-5	N/A	-4	N/A
6/30/2015	14	-6	N/A	-6	N/A
3/31/2015	11	-9	N/A	-5	N/A
12/31/2014	10	-9	N/A	-7	N/A
9/30/2014	8	-12	N/A	-8	N/A
6/30/2014	8	-11	N/A	-16	N/A
3/31/2014	12	-11	N/A	-16	N/A
12/31/2013	15	-12	N/A	-17	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: Insufficient data to determine if UBI's forecast earnings growth is above the savings rate (2.4%).

Ertrag vs. Markt: Insufficient data to determine if UBI's earnings are forecast to grow faster than the Australian market

Hohe Wachstumserträge: Insufficient data to determine if UBI's earnings are expected to grow significantly over the next 3 years.

Einnahmen vs. Markt: Insufficient data to determine if UBI's revenue is forecast to grow faster than the Australian market.

Hohe Wachstumseinnahmen: Insufficient data to determine if UBI's revenue is forecast to grow faster than 20% per year.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Insufficient data to determine if UBI's Return on Equity is forecast to be high in 3 years time

Universal Biosensors Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target increased to AU$1.15

Price target increased to AU$1.15

Consensus revenue estimates fall by 19%

Consensus revenue estimates fall by 10%

Price target increased to AU$1.25

Forecast to breakeven in 2024

Recent updates

New major risk - Financial position

Third quarter 2024 earnings released: AU$0.011 loss per share (vs AU$0.012 loss in 3Q 2023)

Universal Biosensors, Inc. to Report First Half, 2024 Results on Aug 09, 2024

Second quarter 2024 earnings released: AU$0.014 loss per share (vs AU$0.007 profit in 2Q 2023)

Non-Executive Director recently bought AU$50k worth of stock

First quarter 2024 earnings released: AU$0.016 loss per share (vs AU$0.018 loss in 1Q 2023)

Universal Biosensors, Inc., Annual General Meeting, May 30, 2024

New minor risk - Shareholder dilution

Universal Biosensors, Inc., Annual General Meeting, Apr 10, 2024

New minor risk - Shareholder dilution

Chief Executive Officer exercised options to buy AU$259k worth of stock.

Universal Biosensors, Inc. has completed a Follow-on Equity Offering in the amount of AUD 2.5 million.

Universal Biosensors, Inc. to Report Fiscal Year 2023 Results on Mar 07, 2024

Universal Biosensors, Inc. has filed a Follow-on Equity Offering in the amount of AUD 10 million.

We Think Universal Biosensors (ASX:UBI) Needs To Drive Business Growth Carefully

Third quarter 2023 earnings released: AU$0.012 loss per share (vs AU$0.024 loss in 3Q 2022)

New minor risk - Financial position

Second quarter 2023 earnings released: EPS: AU$0.007 (vs AU$0.024 loss in 2Q 2022)

New minor risk - Share price stability

First quarter 2023 earnings released: AU$0.018 loss per share (vs AU$0.025 loss in 1Q 2022)

We're Keeping An Eye On Universal Biosensors' (ASX:UBI) Cash Burn Rate

Full year 2022 earnings: EPS and revenues miss analyst expectations

Universal Biosensors, Inc. Launches New Product, Fructose Test for Sentia

Universal Biosensors, Inc. completes Xprecia Prime clinical trial in USA

Universal Biosensors, Inc. Announces Chairman Changes

We Think Universal Biosensors (ASX:UBI) Needs To Drive Business Growth Carefully

Non-Executive Chairman recently bought AU$54k worth of stock

Price target increased to AU$1.15

Third quarter 2022 earnings released: AU$0.024 loss per share (vs AU$0.016 loss in 3Q 2021)

Price target increased to AU$1.15

We're Keeping An Eye On Universal Biosensors' (ASX:UBI) Cash Burn Rate

Non-Executive Chairman recently bought AU$56k worth of stock

Consensus revenue estimates fall by 19%

Second quarter 2022 earnings released: AU$0.024 loss per share (vs AU$0.01 loss in 2Q 2021)

Consensus revenue estimates fall by 10%

Universal Biosensors, Inc. has completed a Follow-on Equity Offering in the amount of AUD 20.007467 million.

First quarter 2022 earnings released: AU$0.025 loss per share (vs AU$0.008 loss in 1Q 2021)

Universal Biosensors, Inc., Annual General Meeting, Jun 21, 2022

Companies Like Universal Biosensors (ASX:UBI) Are In A Position To Invest In Growth

Price target increased to AU$1.25

Forecast to breakeven in 2024

Universal Biosensors, Inc. Announces Interim Results from the Peter Mac Sponsored Tn Antigen Development Clinical Study

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Universal Biosensors, Inc. Announces the Launch of the Sentia Malic Acid Test into the Global Wine Market

Second quarter 2021 earnings released: AU$0.01 loss per share (vs AU$0.017 loss in 2Q 2020)

We Think Universal Biosensors (ASX:UBI) Can Afford To Drive Business Growth

First quarter 2021 earnings released: AU$0.008 loss per share (vs AU$0.008 loss in 1Q 2020)

Independent Non-Executive Director has left the company

Universal Biosensors, Inc. Announces Resignation of Marshall Heinberg as Director

Full year 2020 earnings released: AU$0.043 loss per share (vs AU$0.027 loss in FY 2019)

Should You Take Comfort From Insider Transactions At Universal Biosensors, Inc. (ASX:UBI)?

Universal Biosensors, Inc. Enters into Non-Exclusive Distribution Agreement with Enartis Inc

We Think Universal Biosensors (ASX:UBI) Can Afford To Drive Business Growth

New 90-day high: AU$0.54

The Universal Biosensors (ASX:UBI) Share Price Has Gained 95% And Shareholders Are Hoping For More

Universal Biosensors, Inc. Releases SENTIA

New 90-day high: AU$0.34

Independent Non-Executive Director recently bought AU$62k worth of stock

Universal Biosensors, Inc. Announces Appointment of Promedeus s.r.o. as Its New Distribution Partner in Czech Republic and Slovak Republic

New 90-day high - AU$0.33

New 90-day high - AU$0.27

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken